Literature DB >> 36048356

Daily Intake of Smallanthus sonchifolius (Yacon) Roots Reduces the Progression of Non-alcoholic Fatty Liver in Rats Fed a High Fructose Diet.

Mariano Nicolás Alemán1,2, Sara Serafina Sánchez1, Stella Maris Honoré3,4.   

Abstract

High-fructose diet is associated with an increased risk of dyslipidemia, metabolic syndrome, and the development of non-alcoholic fatty liver disease (NAFLD) through chronic inflammation. The present study aimed to elucidate the potential benefit of daily consumption of Smallanthus sonchifolius (yacon) roots, rich in fructooligosaccharides (FOS), on the progression to liver fibrosis, in a rat model of NAFLD induced by a high-fructose diet. Male Wistar rats were fed a standard diet (CD, n = 6) or a standard diet plus 10% fructose solution (FD; n = 18). After 20 weeks, FD rats were randomly separated into the following groups (n = 6, each): FD; FD treated with yacon flour (340 mg FOS/body weight; FD + Y) and FD treated with fenofibrate (30 mg/kg body weight; FD + F), for 16 weeks. Daily intake of yacon flour significantly reduced body weight gain, plasma lipid levels, transaminase activities, and improved systemic insulin response in FD rats. In the liver, yacon treatment decreased fructose-induced steatosis and inflammation, and reduced total collagen deposition (64%). Also, yacon decreased TGF-β1 mRNA expression (78%), followed by decreased nuclear localization of p-Smad2/3 in liver tissue. Yacon significantly reduced the expression of α-smooth muscle actin (α-SMA), Col1α1, and Col3α1 mRNAs (85, 44, and 47%, respectively), inhibiting the activation of resident hepatic stellate cells (HSCs). These results suggested that yacon roots have the potential to ameliorate liver damage caused by long-term consumption of a high-fructose diet, being a promising nutritional strategy in NAFLD management.
© 2022. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.

Entities:  

Keywords:  Fibrosis; Liver; Non-alcoholic fatty liver disease; Yacon roots

Year:  2022        PMID: 36048356     DOI: 10.1007/s11130-022-01009-7

Source DB:  PubMed          Journal:  Plant Foods Hum Nutr        ISSN: 0921-9668            Impact factor:   4.124


  29 in total

Review 1.  Fructose and sugar: A major mediator of non-alcoholic fatty liver disease.

Authors:  Thomas Jensen; Manal F Abdelmalek; Shelby Sullivan; Kristen J Nadeau; Melanie Green; Carlos Roncal; Takahiko Nakagawa; Masanari Kuwabara; Yuka Sato; Duk-Hee Kang; Dean R Tolan; Laura G Sanchez-Lozada; Hugo R Rosen; Miguel A Lanaspa; Anna Mae Diehl; Richard J Johnson
Journal:  J Hepatol       Date:  2018-02-02       Impact factor: 25.083

Review 2.  Molecular and cellular mechanisms of liver fibrosis and its regression.

Authors:  Tatiana Kisseleva; David Brenner
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2020-10-30       Impact factor: 46.802

3.  Caffeic acid phenethyl ester inhibits liver fibrosis in rats.

Authors:  Mei Li; Xiu-Fang Wang; Juan-Juan Shi; Ya-Ping Li; Ning Yang; Song Zhai; Shuang-Suo Dang
Journal:  World J Gastroenterol       Date:  2015-04-07       Impact factor: 5.742

4.  Sodium butyrate attenuates high-fat diet-induced steatohepatitis in mice by improving gut microbiota and gastrointestinal barrier.

Authors:  Da Zhou; Qin Pan; Feng-Zhi Xin; Rui-Nan Zhang; Chong-Xin He; Guang-Yu Chen; Chang Liu; Yuan-Wen Chen; Jian-Gao Fan
Journal:  World J Gastroenterol       Date:  2017-01-07       Impact factor: 5.742

Review 5.  What Does the Future Hold for Non-Alcoholic Fatty Liver Disease and Non-Alcoholic Steatohepatitis?

Authors:  Michael Doumas; Konstantinos Imprialos; Konstantinos Stavropoulos; Vasilios G Athyros
Journal:  Curr Vasc Pharmacol       Date:  2019       Impact factor: 2.719

Review 6.  Beneficial Effects of Plant-Derived Natural Products on Non-alcoholic Fatty Liver Disease.

Authors:  Luis E Simental-Mendía; Claudia I Gamboa-Gómez; Fernando Guerrero-Romero; Mario Simental-Mendía; Adriana Sánchez-García; Mariana Rodríguez-Ramírez
Journal:  Adv Exp Med Biol       Date:  2021       Impact factor: 2.622

Review 7.  Non-alcoholic fatty liver disease.

Authors:  Elizabeth E Powell; Vincent Wai-Sun Wong; Mary Rinella
Journal:  Lancet       Date:  2021-04-21       Impact factor: 79.321

8.  Identifying nonalcoholic fatty liver disease patients with active fibrosis by measuring extracellular matrix remodeling rates in tissue and blood.

Authors:  Martin L Decaris; Kelvin W Li; Claire L Emson; Michelle Gatmaitan; Shanshan Liu; Yenny Wang; Edna Nyangau; Marc Colangelo; Thomas E Angel; Carine Beysen; Jeffrey Cui; Carolyn Hernandez; Len Lazaro; David A Brenner; Scott M Turner; Marc K Hellerstein; Rohit Loomba
Journal:  Hepatology       Date:  2016-11-15       Impact factor: 17.425

Review 9.  Non-Alcoholic Steatohepatitis: A Review of Its Mechanism, Models and Medical Treatments.

Authors:  Cheng Peng; Alastair G Stewart; Owen L Woodman; Rebecca H Ritchie; Cheng Xue Qin
Journal:  Front Pharmacol       Date:  2020-12-03       Impact factor: 5.810

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.